In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent

Journal of Chemotherapy

Volumn 13, Issue 3, 2001, Pages 244-254

  Jones, R N ^a   Biedenbach, D J ^a   Johnson, D M ^a   Pfaller, M A ^a  

^a JMI LABORATORIES   (United States)

Author keywords

BI 397; Glycopeptides; Gram positive bacteria; Resistance

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GLYCOPEPTIDE; LINCOSAMIDE; MDL 62476; OXACILLIN; PENICILLIN G; STREPTOGRAMIN; TEICOPLANIN; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIOSTASIS; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CORYNEBACTERIUM; CULTURE MEDIUM; DRUG STRUCTURE; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0034979095     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2001.13.3.244     Document Type: Article

References (25)

1. Gram-positive resistance: Challenge for the development of new antibiotics
2. Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America
3. Control of antimicrobial resistance problems in the critical care unit
4. The changing pattern of infection in neutropenic patients
5. Multiple antibiotic-resistant bacteria in long-term-care facilities: An emerging problem in the practice of infectious diseases
6. Methicillin-resistant staphylococci in a general hospital
7. Vancomycin-intermediate and -resistant Staphylococcus aureus: What the infectious disease specialist needs to know
8. Antimicrobial resistance in intensive care units
9. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991
10. Emergence of vancomycin resistance in coagulase-negative staphylococci
11. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci
12. Nationwide German multicenter study on prevalence of antibiotic resistance in staphylococcal bloodstream isolates and comparative in vitro activities of quinupristin/dalfopristin
13. Vancomycin-resistant enterococci
14. Current perspectives on glycopeptide resistance
15. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential
16. Oxazolidinones. A review
17. Antimicrobial activity of quinupristin/dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada
18. In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: A multicentre international trial
19. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic
20. Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic
21. In vitro activity of the semisynthetic glycopeptide amide MDL 63,246
22. BI 397: A new developmental semisynthetic glycopeptide antibiotic